Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | ITGAL | P20701 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CRHBP | P24387 | 2/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23183087 | 0.71 | NISCH (0.53) | MAOAMAOBNISCHLMNASMN1; SMN2 | |
| SCHEMBL3766975 | 0.71 | MEN1 (0.45) | CA2MAOBNISCHLMNA | |
| SCHEMBL29194950 | 0.69 | PIM1 (0.34) | ABCG2ITGB2ICAM1ITGALCA2 | |
| SCHEMBL3655783 | 0.69 | ABCG2 (0.36) | ABCG2ITGB2ICAM1ITGALCA2 | |
| SCHEMBL329447 | 0.69 | MAOA (0.46) | ABCG2ITGB2ICAM1ITGALCA2 | |
| SCHEMBL353825 | 0.69 | PARP1 (0.40) | ABCG2ITGB2ICAM1ITGALCA2 | |
| SCHEMBL8525523 | 0.69 | POLB (0.43) | ABCG2ITGB2ICAM1ITGALCA2 | |
| SCHEMBL446185 | 0.69 | ABCG2 (0.36) | ABCG2ITGB2ICAM1ITGALCA2 | |
| SCHEMBL11307666 | 0.69 | ABCG2 (0.36) | ABCG2ITGB2ICAM1ITGALCA2 | |
| SCHEMBL312107 | 0.69 | ABCG2 (0.36) | ABCG2ITGB2ICAM1ITGALCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117835980-A | Tetrahydropyrazolopyridine analog ligand of NLRX1 and application thereof | 朗多生物制药股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-3927427-B1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | NIMMUNE BIOPHARMA INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230357744-A1 | ENGINEERED TRYPTOPHAN DECARBOXYLASES AND USES THEREOF FOR SYNTHESIZING TRYPTAMINE ANALOGS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-11-09 | — | — | US | disclosed |
| EP-4214200-A1 | LANCL LIGANDS | Nimmune Biopharma, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-116368133-A | NLRX1 ligand | 朗多生物制药股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230192652-A1 | PLXDC2 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4196475-A1 | NLRX1 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20230167083-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230128450-A1 | NLRX1 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-11597717-B2 | Substituted imidazoles as PLXDC2 ligands | LANDOS BIOPHARMA, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20090030014-A1 | Indole Derivative Having Pgd2 Receptor Antagonist Activity | SHIONOGI & CO., LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1939175-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi&Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1932839-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-06-18 | — | — | EP | disclosed |
| EP-1916245-A1 | INDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-04-30 | — | — | EP | disclosed |
| EP-1911759-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-0938483-B1 | MUSCARINIC ANTAGONISTS | SCHERING CORP (US) | 2003-02-26 | — | — | EP | disclosed |
| US-6043255-A | ADMINISTERING TO A PATIENT SUFFERING FROM COGNITIVE DISORDER IN NEURODEGENERATIVE DISEASES A 1,4-DI-SUBSTITUTED PIPERIDINE COMPOUND | SCHERING CORPORATION (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0938483-A2 | MUSCARINIC ANTAGONISTS | SCHERING CORPORATION (US) | 1999-09-01 | — | — | EP | disclosed |
| US-5889006-A | Muscarinic antagonists | SCHERING CORPORATION (US) | 1999-03-30 | — | — | US | disclosed |
| WO-1998005292-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE AS MUSCARINIC ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128450-A1 | NLRX1 LIGANDS | NLRP3, NLRP1, NOD1 | ABCG2 2888/4885ITGB2 3226/4885ICAM1 520/4885 |
| US-20230167083-A1 | LANCL LIGANDS | LANCL2, LANCL1, LCLAT1 | ABCG2 2807/4885ITGB2 3933/4885ICAM1 1328/4885 |
| US-20230192652-A1 | PLXDC2 LIGANDS | PLP2, PDCD1LG2, LCP2 | ABCG2 3537/4885ITGB2 999/4885ICAM1 590/4885 |
| US-11597717-B2 | Substituted imidazoles as PLXDC2 ligands | PLK2, PLEC, PLP2 | ABCG2 1929/4885ITGB2 1074/4885ICAM1 456/4885 |
| US-20090030014-A1 | Indole Derivative Having Pgd2 Receptor Antagonist Activity | HRH2, PTGDR, CNR2 | ABCG2 320/4885ITGB2 3549/4885ICAM1 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.